65th ASH Annual Meeting & Exposition: 723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes

Symposia: Allogeneic Transplantation: Long-term Follow-up and Disease Recurrence Oral and Poster Abstracts
Oral

Research, Fundamental Science, Translational Research

Room 11 (San Diego Convention Center)

Moderators:

John DiPersio, Washington University School of Medicine and Remy Dulery, MD, PhD, Sorbonne University, Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris, INSERM UMRs 938

Disclosures:

DiPersio: Vertex: Consultancy; Macrogenics: Research Funding; Bioline: Consultancy; Rivervest: Consultancy; Magenta: Current holder of stock options in a privately-held company, Other: Ownership Investment, Patents & Royalties; WUGEN: Current holder of stock options in a privately-held company, Other: Ownership Investment, Patents & Royalties, Research Funding. Dulery: Ligue Nationale contre le Cancer: Research Funding; Arthur Sachs Scholarships: Research Funding; Servier Foundation: Research Funding; Monahan Foundation: Research Funding; Philippe Foundation: Research Funding; DPC AP-HP: Research Funding; Novartis: Honoraria; Takeda: Honoraria; Kite Pharma / Gilead: Other: Registration fees for scientific meetings and travel accommodations .

This oral abstract symposium highlights novel basic and translational research focused on optimizing post-transplant survival and disease relapse by identifying mechanisms that may enhance the graft-vs-tumor effect, including understanding pathways that contribute to leukemia escape or resistance after allogeneic transplantation.

4:00 PM

361

An Analytic Framework for the Prediction of Gvl Minor Histocompatibility Antigens to Prevent or Treat Post-Transplant Relapse

Nicoletta Cieri, MD, PhD^1,2,3, Liang Li, MS⁴^*, Nidhi Hookeri^1,2^*, Kari Stromhaug^1,2^*, Julia Keating, MS⁵^*, Jonathan Stevens⁶^*, Kameron Kooshesh, MD³, Helen Ji²^*, Gabrielle M. Hernandez¹^*, Jennifer Abelin, PhD¹^*, Susan Klaeger, PhD¹^*, Cleo Forman⁵^*, Karl Clauser¹^*, Siranush Sarkizova, PhD¹^*, Giacomo Oliveira, PhD^2,3^*, Livius Penter, MD^1,2,3, Haesook T. Kim, PhD⁵, William Lane, MD, PhD⁶^*, Shuqiang Li, PhD⁷^*, Kenneth J. Livak, PhD⁷^*, Steven A. Carr, PhD¹^*, Derin B. Keskin⁷^*, Vincent T. Ho, MD^2,3^*, Jerome Ritz, MD^2,3, Robert J. Soiffer, MD^2,3, Donna S. Neuberg, ScD⁵, Chip Stewart, PhD¹^*, Gad Getz, PhD^3,4,8^* and Catherine J Wu, MD^1,2,3

¹Broad Institute of MIT and Harvard, Cambridge, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Harvard Medical School, Boston, MA
⁴Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
⁵Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁶Brigham and Women's Hospital, Boston, MA
⁷Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
⁸Cancer Center, Massachusetts General Hospital, Boston, MA

4:15 PM

362

Time of Origin and Environmental Drivers of Leukemia Immune Escape after Transplantation

Cristina Toffalori¹^*, Riccardo Bergamin²^*, Alice Antonello²^*, Anna Francesca Tortorelli¹^*, Giorgio Orofino^1,3^*, Matteo Cristante¹^*, Lucrezia Della Volpe⁴^*, Salvatore Milite²^*, Nicola Calonaci²^*, Giorgia Gandolfi⁵^*, Aurora Maurizio⁵^*, Raffaella Greco³^*, Gabriele Bucci⁵^*, Dejan Lazarevic⁵^*, Raffaella Di Micco⁴^*, Giovanni Tonon^5,6^*, Fabio Ciceri^3,6^*, Giulio Caravagna²^* and Luca Vago, MD, PhD^1,6,7

¹Unit of Immunogenetics, Leukemia Genomics and Immunobiology, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy
²Cancer Data Science Lab, University of Trieste, Trieste, Italy
³Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. Ospedale San Raffaele, Milan, Italy
⁴Senescence in Stem Cell Ageing, Differentiation and Cancer Unit, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), I.R.C.C.S. Ospedale San Raffaele, Milano, Italy
⁵Center for Omic Sciences at San Raffaele (COSR), I.R.C.C.S. Ospedale San Raffaele, Milano, Italy
⁶Vita-Salute San Raffaele University, Milan, Italy
⁷Hematology and Bone Marrow Transplantation Unit, I.R.C.C.S. Ospedale San Raffaele, Milano, NA, Italy

4:30 PM

363

Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft Versus Leukemia Response with Adoptive Cellular Therapy

Alexandria Maurer, MD, PhD^1,2,3, Cameron Y Park, MS^4,5^*, Shouvik Mani, MS^4,5^*, Mehdi Borji, MS^3,6,7^*, Crystal Shin, BS^4,5^*, Livius Penter, MD^2,3,6,8, James R Brenner, BS^6,9^*, Jackson Southard, BS⁶^*, Wesley S Lu, BS^6,7^*, Haoxiang Lyu, BS^6,7^*, Shuqiang Li, PhD^6,7^*, Kenneth J. Livak, PhD^6,7^*, Jerome Ritz, MD^2,6, Robert J. Soiffer, MD^2,6, Elham Azizi^4,5^* and Catherine J Wu, MD^2,3,6

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
²Harvard Medical School, Boston, MA
³Broad Institute of MIT and Harvard, Cambridge, MA
⁴Department of Biomedical Engineering, Columbia University, New York, NY
⁵Irving Institute for Cancer Dynamics, Columbia University, New York, NY
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁷Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
⁸Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Berlin, Germany
⁹Biological & Biomedical Sciences Program, Harvard Medical School, Harvard University, Boston, MA

4:45 PM

364

ASXL1 Truncating Mutations Drive Leukemic Resistance to T Cell Attack

Dustin McCurry, MD¹, Zhongqi Ge, PhD¹^*, Jaehyun Lee¹^*, Pranaya Raparla¹^*, Thomas Koehnke, MD², Rishi Pasumarthi¹^*, Xiaohong Leng, PhD¹^*, Oren Pasvolsky, MD³^*, Vinhkhang Nguyen⁴^*, Katie Maurer, MD, PhD⁵, Shuqiang Li, PhD⁶^*, Kenneth J. Livak, PhD⁶^*, Elham Azizi⁷^*, Robert J. Soiffer, MD⁵, Sachet Shukla, PhD⁸^*, Ravi Majeti, MD⁹, Jerome Ritz, MD⁵, Catherine J Wu, MD⁵, Jeffrey J. Molldrem, MD¹⁰ and Pavan Bachireddy, MD¹

¹The University of Texas MD Anderson Cancer Center, Houston, TX
²Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
⁴University of California San Francisco, San Francisco
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA
⁷Department of Biomedical Engineering, Columbia University, New York, NY
⁸Department of Hematopoietic Biology & Malignancy, The University of Texas M.D. Anderson Cancer Center, Houston
⁹Stanford University School of Medicine, Stanford, CA
¹⁰Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX

5:00 PM

365

Donor Hematopoietic Cell Telomere Length and Magnitude of Post-HCT Shortening Predict Survival in Early Stage Leukemia and Myelodysplastic Syndrome

Shahinaz M. Gadalla, MD, PhD¹, Hormuzd Katki, PhD²^*, Tsung-Po Lai, PhD³^*, Casey Dagnall⁴^*, Caitrin Bupp, MPH⁵^*, Amy Hutchinson⁶^*, James Anderson⁷^*, Kyra Mendez⁸^*, Stephen R. Spellman, MBS⁹^*, Valerie Stewart, MSc, PhD¹⁰^*, Sharon A Savage, MD¹, Stephanie J. Lee^7,11, John Levine, MD¹², Wael Saber, MD, MS¹³ and Abraham Aviv¹⁴^*

¹Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD
²NCI, Rockville, MD
³New Jersey Medical School, Newark, NJ
⁴Frederick National Laboratory for Cancer Research, Rockville, MD
⁵CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis
⁶Frederick National Laboratory for Cancer Research, Rockville
⁷University of Washington, Seattle, WA
⁸National Cancer Institute, Rockville
⁹CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN
¹⁰Center for International Blood and Marrow Transplant Research, Minneapolis
¹¹Fred Hutchinson Cancer Center, Seattle, WA
¹²Icahn School of Medicine at Mount Sinai, New York, NY
¹³Center for International Blood and Marrow Transplant Research, Minneapolis, MN
¹⁴New Jersey Medical School, NJ

5:15 PM

366

Deciphering the Impact of Donor Telomere Length on Allogeneic Transplantation Outcomes: Telomere Length Matters More Than Age

Hengwei Wu, MD^1,2,3,4^*, Zhiyang Yuan, PhD⁵^*, Xiang Xu, PhD⁵^*, Jimin Shi^1,2,3,4^*, Yi Luo^1,2,3,4^*, Jian Yu^1,2,3,4^*, Xiaoyu Lai^1,2,3,4^*, Lizhen Liu^1,2,3,4^*, Yamin Tan, MD⁶^*, Huarui Fu^1,2,3,4^*, Pengxu Qian, PhD^2,3,4^*, Zhongzheng Zheng, PhD⁵^*, He Huang, MD^1,2,3,4^* and Yanmin Zhao^1,2,3,4^*

¹Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
²Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University, Hangzhou, China
³Institute of Hematology, Zhejiang University, Hangzhou, China
⁴Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Zhejiang University, Hangzhou, China
⁵Shanghai Tissuebank Biotechnology Co., Ltd, Shanghai, China
⁶Zhejiang Cancer Hospital, Hangzhou, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

723.O2.6 723. Allogeneic Transplantation: Long-Term Follow-Up and Disease Recurrence: Basic and Translational: Optimizing Post-Transplant Outcomes